Common gut bacteria may interfere with the effectiveness of widely used medications for conditions such as migraines, depression, type 2 diabetes, and prostate cancer, a new study has revealed.

Common gut bacteria can metabolise some oral medications potentially rendering these important drugs against migraines, depression, type 2 diabetes, and prostate cancer less ...

A new study, published today in Nature Chemistry by researchers from the University of Pittsburgh and Yale University , shows how common gut ...

A study published in Nature Chemistry by researchers from the University of Pittsburgh and Yale University shows how common ...

Researchers have found that gut bacteria can interfere with the effectiveness of over 400 commonly used medications that ...

American Century Companies Inc. increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) ...

Both ibuprofen and naproxen potently inhibit hTAS1R2–TAS1R3 receptors that sense sweetness in a dose-dependent manner. The ...

Structure Therapeutics Inc.’s GPCR share price has dipped by 12.27%, which has investors questioning if this is right time to buy.

Skye Bioscience, Inc.’s SKYE share price has dipped by 12.88%, which has investors questioning if this is right time to buy.

Septerna, Inc. ( ($SEPN) ) has released its Q4 earnings. Here is a breakdown of the information Septerna, Inc. presented to its investors.

G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...